60064-34-8

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 2-amino-4-chlorobenzoate is used as an anti-inflammatory and analgesic agent for its potential therapeutic effects in reducing inflammation and pain.
Used in Chemical Synthesis:
Ethyl 2-amino-4-chlorobenzoate is used as a key intermediate in the synthesis of other organic compounds, contributing to the development of new pharmaceuticals and chemical products.
Used in Industrial Applications:
Ethyl 2-amino-4-chlorobenzoate may have various industrial applications, although specific uses are not detailed in the provided materials. Its versatility as a chemical intermediate suggests potential in multiple sectors.
It is important to handle Ethyl 2-amino-4-chlorobenzoate with caution, as it can be hazardous if not properly managed and can cause irritation upon contact with skin or eyes.

Upstream product

• 64-17-5 ethanol 
• 89-77-0 2-Amino-4-chlorobenzoic acid 

Downstream Products

• 139422-21-2 ethyl 2-(cyanoacetamido)-4-chlorobenzoate 
• 116434-94-7 4,7-dichloro-2-phenylquinoline 
• 1038343-14-4 C₁₆H₁₂ClF₂NO₃ 
• 1038343-18-8 C₁₆H₁₂Cl₃NO₃ 
• 139422-18-7 2-(ethoxycarbonyl)-5-chlorophenyl isocyanate 
• 110802-16-9 4-hydroxy-7-chloro-2-phenylquinoline 
• 1156116-58-3 C₁₅H₁₃ClN₂O₃ 
• 1352126-77-2 2-[2-(2-fluorobenzoylamino)-benzoylamino]-4-chlorobenzoic acid 
• 37585-16-3 (2-amino-4-chlorophenyl)methanol 

Relevant academic research and scientific papers

Overcoming the Deallylation Problem: Palladium(II)-Catalyzed Chemo-, Regio-, and Stereoselective Allylic Oxidation of Aryl Allyl Ether, Amine, and Amino Acids

We report herein a Pd(II)/bis-sulfoxide-catalyzed intramolecular allylic C-H acetoxylation of aryl allyl ether, amine, and amino acids with the retention of a labile allyl moiety. Mechanistically, the reaction proceeds through a distinct double-bond isomerization from the allylic to the vinylic position followed by intramolecular carboxypalladation and the β-hydride elimination pathway. For the first time, C-H oxidation of N-allyl-protected amino acids to furnish five-membered heterocycles through 1,3-syn-addition is established with excellent diastereoselectivity.

ANTIVIRAL COMPOUNDS

The present invention provides new antiviral compounds and pharmacological compositions comprising these new compounds and their use in the prophylaxis, prevention and treatment of viral infections, particularly adenovirus and herpes virus infections.

Synthesis, biological evaluation, and structure-activity relationships of 2-[2-(benzoylamino)benzoylamino]benzoic acid analogues as inhibitors of adenovirus replication

2-[2-Benzoylamino)benzoylamino]benzoic acid (1) was previously identified as a potent and nontoxic antiadenoviral compound (Antimicrob. Agents Chemother. 2010, 54, 3871). Here, the potency of 1 was improved over three generations of compounds. We found that the ortho, ortho substituent pattern and the presence of the carboxylic acid of 1 are favorable for this class of compounds and that the direction of the amide bonds (as in 1) is obligatory. Some variability in the N-terminal moiety was tolerated, but benzamides appear to be preferred. The substituents on the middle and C-terminal rings were varied, resulting in two potent inhibitors, 35g and 35j, with EC50 = 0.6 μM and low cell toxicity.

NEW ANTIVIRAL COMPOUNDS

The present invention provides new antiviral compounds and pharmacological compositions comprising these new compounds and their use in the prophylaxis, prevention and treatment of viral infections, particularly adenovirus and herpes virus infections.

Synthesis and anti-platelet evaluation of 2-benzoylaminobenzoate analogs

Fifty-two 2-benzoylaminobenzoate analogs were synthesized and subjected to anti-platelet aggregation assay using arachidonic acid (AA), collagen (Col), thrombin (Thr), and U46619 as inducers. The results revealed that most of 2-benzoylaminobenzoic acid derivatives showed a selectively inhibitory effect on AA-induced platelet aggregation. As a result of the 2-benzoylaminobenzoic acid derivatives (18, 44, and 46), there were no inhibitory effects on platelet aggregation induced by U46619, but these elicited an inhibitory effect on thromboxane B2 formation at 1.0 μM. These 2-benzoylaminobenzoate analogs were therefore proposed as cyclooxygenase inhibitors.